Fresenius Medical Care Reports Q1 2026 Results Amid Revenue Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy FMS?
Source: Investing
Fresenius Medical Care's stock fell by 10.91% as it crossed below the 5-day SMA, reflecting investor concerns following its Q1 2026 financial results.
The company reported a non-GAAP EPS of €0.91 for Q1 2026, despite a 5.5% year-over-year revenue decline to €4.61 billion. While operating cash flow surged by 39% to €227 million, the overall outlook for 2026 revenue growth remains broadly flat, which may have contributed to the stock's decline amid broader market strength.
Investors are likely weighing the company's strong cash flow growth against the backdrop of declining revenues, leading to a cautious sentiment in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FMS
Wall Street analysts forecast FMS stock price to rise
2 Analyst Rating
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 21.650
Low
22.00
Averages
25.00
High
28.00
Current: 21.650
Low
22.00
Averages
25.00
High
28.00
About FMS
Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fresenius Medical Care Shares Enter Oversold Territory
- Oversold Signal: Fresenius Medical Care's stock price fell to $20.02 per share on Tuesday, resulting in an RSI of 27.2, indicating an oversold condition that may attract bullish investors looking for buying opportunities.
- Market Comparison: In contrast, the current RSI of the S&P 500 ETF (SPY) stands at 71.6, highlighting the stark difference in market conditions and potentially drawing investor attention to FMS's situation.
- Historical Performance: FMS's 52-week low is $20.02, with a high of $30.46, and the last trade was at $20.19, indicating that the stock is hovering at a low level, which may present potential rebound opportunities for investors.
- Investor Sentiment: While the stock is currently at a low price, investors should carefully assess market sentiment and technical indicators to determine whether to enter at this time, avoiding further downside risks.
See More
Fresenius Medical Care Q1 2026 Financial Results
- Non-GAAP EPS: Fresenius Medical Care reported a non-GAAP EPS of €0.91 for Q1 2026, despite a 5.5% year-over-year revenue decline to €4.61 billion, indicating resilience in profitability amidst challenging conditions.
- Significant Cash Flow Growth: Operating cash flow surged by 39% to €227 million in Q1 2026, improving the margin from 3.3% in 2025 to 4.9%, reflecting enhanced cash management and operational efficiency.
- Substantial Free Cash Flow Increase: Free cash flow rose by 94% to €40 million in Q1 2026, with the margin increasing from 0.4% to 0.9%, providing greater flexibility for future investments and debt management.
- Slight Debt Increase: Total net debt and lease liabilities slightly increased to €9.79 billion from €9.753 billion in 2025; however, the company confirmed its outlook for 2026 revenue growth to remain broadly flat, demonstrating confidence in future performance.
See More
European Stocks Expected to Open Lower Amid Iran Conflict Concerns
- Market Reaction: European stocks are expected to open mostly lower on Tuesday as the fragile ceasefire between the U.S. and Iran appears close to collapse, with Germany's DAX and France's CAC 40 down 0.4% each, and Italy's FTSE MIB down 0.1%, indicating investor sensitivity to geopolitical risks.
- Oil Price Volatility: Oil prices surged on Monday as traders assessed Middle East developments, reflecting concerns over the potential for prolonged conflict to lead to a global recession, although prices declined overnight.
- U.S. Warning: President Trump warned Iran in a Fox News interview that it would be
See More
Fresenius Medical Care Q1 Earnings Preview
- Earnings Announcement Date: Fresenius Medical Care is set to announce its Q1 2023 earnings on May 5 before market open, with consensus EPS estimate at €0.59, reflecting a significant 29.8% year-over-year decline, which could impact investor sentiment.
- Revenue Expectations: The revenue estimate for Q1 stands at €5.42 billion, representing an 11.0% year-over-year increase, indicating resilience in the company's market position despite the pressure on EPS.
- Historical Performance Review: Over the past two years, Fresenius has beaten EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's stability and reliability in financial performance.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward and one downward revision, while revenue estimates experienced no upward revisions and three downward adjustments, reflecting a cautious market outlook on the company's future performance.
See More
Humacyte Regains Exclusive Rights for Symvess Outside the U.S.
- Agreement Amendment: Humacyte (HUMA) amended its agreement with Fresenius Medical Care (FMS) on April 21, regaining exclusive rights to develop and commercialize Symvess outside the U.S., marking a strategic return to the global market.
- Product Background: Symvess received FDA approval in 2024 for extremity vascular trauma, and this move allows Humacyte to directly manage product development and regulatory matters in international markets.
- Financial Arrangement: Under the amended agreement, Humacyte will pay Fresenius low-single-digit royalties on overseas net sales after a two-year royalty-free period, supporting potential revenue growth for the company.
- Market Potential: The regained rights will enable Humacyte to respond more flexibly to international market demands, particularly in the Middle East, where it recently secured a $1.48 million purchase commitment for Symvess from Saudi Arabia, further enhancing its competitive position.
See More
Focus Graphite Advances Infrastructure Development for Lac Knife Project
- Infrastructure Assessment: Focus Graphite has engaged Norda-Stelo to conduct a corridor selection and preliminary evaluation for access road and powerline infrastructure for the Lac Knife Project, with results expected by the end of May 2026, facilitating environmental baseline work and geotechnical surveys for future development phases.
- Improved Accessibility: The proposed all-season access road will link Lac Knife to the upgraded Highway 389, enhancing transportation efficiency for personnel and equipment, improving mine construction logistics, and ensuring a safer and more reliable work environment for operations.
- Funding Application Progress: The company has applied for federal and provincial infrastructure funding to support the development of the access road and powerline, aligning with government priorities for critical minerals development and northern infrastructure investment, which is expected to boost regional economic growth.
- Equity Conversion Support: Chairman Jeff York has converted C$500,000 of his loan into 1,388,889 common shares, demonstrating his ongoing commitment to the company and strengthening Focus Graphite's capital base to support future growth.
See More
Fresenius Medical Care Shares Enter Oversold Territory
- Oversold Signal: Fresenius Medical Care's stock price fell to $20.02 per share on Tuesday, resulting in an RSI of 27.2, indicating an oversold condition that may attract bullish investors looking for buying opportunities.
- Market Comparison: In contrast, the current RSI of the S&P 500 ETF (SPY) stands at 71.6, highlighting the stark difference in market conditions and potentially drawing investor attention to FMS's situation.
- Historical Performance: FMS's 52-week low is $20.02, with a high of $30.46, and the last trade was at $20.19, indicating that the stock is hovering at a low level, which may present potential rebound opportunities for investors.
- Investor Sentiment: While the stock is currently at a low price, investors should carefully assess market sentiment and technical indicators to determine whether to enter at this time, avoiding further downside risks.
See More
Fresenius Medical Care Q1 2026 Financial Results
- Non-GAAP EPS: Fresenius Medical Care reported a non-GAAP EPS of €0.91 for Q1 2026, despite a 5.5% year-over-year revenue decline to €4.61 billion, indicating resilience in profitability amidst challenging conditions.
- Significant Cash Flow Growth: Operating cash flow surged by 39% to €227 million in Q1 2026, improving the margin from 3.3% in 2025 to 4.9%, reflecting enhanced cash management and operational efficiency.
- Substantial Free Cash Flow Increase: Free cash flow rose by 94% to €40 million in Q1 2026, with the margin increasing from 0.4% to 0.9%, providing greater flexibility for future investments and debt management.
- Slight Debt Increase: Total net debt and lease liabilities slightly increased to €9.79 billion from €9.753 billion in 2025; however, the company confirmed its outlook for 2026 revenue growth to remain broadly flat, demonstrating confidence in future performance.
See More
European Stocks Expected to Open Lower Amid Iran Conflict Concerns
- Market Reaction: European stocks are expected to open mostly lower on Tuesday as the fragile ceasefire between the U.S. and Iran appears close to collapse, with Germany's DAX and France's CAC 40 down 0.4% each, and Italy's FTSE MIB down 0.1%, indicating investor sensitivity to geopolitical risks.
- Oil Price Volatility: Oil prices surged on Monday as traders assessed Middle East developments, reflecting concerns over the potential for prolonged conflict to lead to a global recession, although prices declined overnight.
- U.S. Warning: President Trump warned Iran in a Fox News interview that it would be
See More
Fresenius Medical Care Q1 Earnings Preview
- Earnings Announcement Date: Fresenius Medical Care is set to announce its Q1 2023 earnings on May 5 before market open, with consensus EPS estimate at €0.59, reflecting a significant 29.8% year-over-year decline, which could impact investor sentiment.
- Revenue Expectations: The revenue estimate for Q1 stands at €5.42 billion, representing an 11.0% year-over-year increase, indicating resilience in the company's market position despite the pressure on EPS.
- Historical Performance Review: Over the past two years, Fresenius has beaten EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's stability and reliability in financial performance.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward and one downward revision, while revenue estimates experienced no upward revisions and three downward adjustments, reflecting a cautious market outlook on the company's future performance.
See More
Humacyte Regains Exclusive Rights for Symvess Outside the U.S.
- Agreement Amendment: Humacyte (HUMA) amended its agreement with Fresenius Medical Care (FMS) on April 21, regaining exclusive rights to develop and commercialize Symvess outside the U.S., marking a strategic return to the global market.
- Product Background: Symvess received FDA approval in 2024 for extremity vascular trauma, and this move allows Humacyte to directly manage product development and regulatory matters in international markets.
- Financial Arrangement: Under the amended agreement, Humacyte will pay Fresenius low-single-digit royalties on overseas net sales after a two-year royalty-free period, supporting potential revenue growth for the company.
- Market Potential: The regained rights will enable Humacyte to respond more flexibly to international market demands, particularly in the Middle East, where it recently secured a $1.48 million purchase commitment for Symvess from Saudi Arabia, further enhancing its competitive position.
See More
Focus Graphite Advances Infrastructure Development for Lac Knife Project
- Infrastructure Assessment: Focus Graphite has engaged Norda-Stelo to conduct a corridor selection and preliminary evaluation for access road and powerline infrastructure for the Lac Knife Project, with results expected by the end of May 2026, facilitating environmental baseline work and geotechnical surveys for future development phases.
- Improved Accessibility: The proposed all-season access road will link Lac Knife to the upgraded Highway 389, enhancing transportation efficiency for personnel and equipment, improving mine construction logistics, and ensuring a safer and more reliable work environment for operations.
- Funding Application Progress: The company has applied for federal and provincial infrastructure funding to support the development of the access road and powerline, aligning with government priorities for critical minerals development and northern infrastructure investment, which is expected to boost regional economic growth.
- Equity Conversion Support: Chairman Jeff York has converted C$500,000 of his loan into 1,388,889 common shares, demonstrating his ongoing commitment to the company and strengthening Focus Graphite's capital base to support future growth.
See More
